Shire's Human Genetic Therapies unit will work with Atlas' staff in a similar way to the partnership struck between the VC firm and crops company Monsanto for life sciences companies in April.
Atlas Venture, an early-stage venture capital firm, has entered into a multi-year collaboration with drugs company Shire to back start-ups working on rare disease therapeutics and with potential options to buy the portfolio companies for set prices.
Shire’s Human Genetic Therapies unit will work with Atlas’ staff in a similar way to the partnership struck between the VC firm and crops company Monsanto for life sciences companies in April.
